New sleep drug shows promise for liver patients
NCT ID NCT07480096
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a sleep medication called lemborexant in 82 adults with liver cirrhosis who had trouble sleeping. The drug works by blocking wakefulness signals in the brain. Researchers measured sleep quality and checked for side effects on the liver. The goal was to see if lemborexant is a safe and effective option for this group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lemborexant
What this could lead to
If it works, this could offer a safer sleep medication for people with liver cirrhosis, improving their quality of life without harming the liver.
What could go wrong
This is a small, early-phase trial (82 participants). The results may not apply to all cirrhosis patients, and long-term safety is not yet known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hepatobiliary Division, Internal Medicine Department, Dr Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
Jakarta, DKI Jakarta, 10430, Indonesia